Brokerages predict that Bellerophon Therapeutics Inc (NASDAQ:BLPH) will announce earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics posted earnings per share of ($0.35) in the same quarter last year, which suggests a positive year over year growth rate of 31.4%. The business is expected to announce its next quarterly earnings results on Monday, March 12th.
On average, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($1.18) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.98) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Bellerophon Therapeutics.
Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, hitting the consensus estimate of ($0.22).
Bellerophon Therapeutics (NASDAQ BLPH) opened at $2.18 on Friday. The firm has a market cap of $77.06 and a PE ratio of -1.68. Bellerophon Therapeutics has a 52 week low of $0.61 and a 52 week high of $2.74.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/19/brokerages-anticipate-bellerophon-therapeutics-inc-blph-to-announce-0-24-earnings-per-share.html.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.